



Post Authorisation Assessments

Rycarfa 50 mg Tablets for Dogs

Vm 01656/4070

18 February 2026	Submission of an updated Ph. Eur. CEP for an active substance. (NI)
19 December 2025	Submission of an updated Ph. Eur. CEP for an active substance.
20 October 2025	One-off alignment of the product information with version 9.0* of the QRD templates.
27 February 2024	Submission of an updated certificate of suitability. (NI)
12 January 2023	Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
17 April 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
23 February 2023	Change to comply with Ph. Eur. reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
28 December 2022	Updated certificate of suitability from an already approved manufacturer.
08 March 2022	Minor change to an approved test procedure for the active substance.
16 December 2021	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
12 November 2021	Minor changes to an approved test procedure of the finished product.
22 April 2020	Minor change in the manufacturing process of the finished product. Minor change in the manufacturing process of the finished product.
25 February 2020	Changes to the labelling and package leaflet.
06 February 2020	Addition of a manufacturer responsible for batch release including batch control/testing. Addition of a manufacturing site of the finished product.
16 December 2019	Deletion of manufacturing site for a finished product. Addition of a secondary packaging site of the finished product. Addition of a primary packaging site of the finished product.
10 December 2019	Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.
12 November 2019	Change in the manufacturer of a starting material used in the manufacturing process of the active substance.

11 June 2019	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
19 February 2019	Renewal – UK as CMS.
10 May 2017	Minor change to the restricted part of an Active Substance Master File.
19 May 2015	Addition of UK local representative information to the package leaflet.
08 September 2014	Variation to extend the maximum holding time for the finished product packaged in PE/Alu triplex bags, from 2 months to 12 months.